Trial Profile

A Multicenter, Randomized, Double-blind, Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 23 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Jan 2024 Primary endpoint has been met. (Time to sustained recovery of 11 COVID-19 symptoms)
18 Jan 2024 Results published in the New England Journal of Medicine
09 May 2023 Last checked against ClinicalTrials.gov: US National Institutes of Health record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com